Genitourinary Cancers

Edwin M. Posadas, MD, discusses the evolution of prostate cancer therapy, including the earlier use of advanced-stage agents and the potential for immunotherapy in the field.

Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.

Howard M. Sandler, MD, chair, Department of Radiation Oncology, Ronald H. Bloom Family Chair in Cancer Therapeutics, director, Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses hypofractionation in prostate cancer.

Mark Tyson, MD, discusses the management of localized advanced bladder cancer, the promise of immunotherapy, and his advice for urologists treating patients with bladder cancer.

Hyung L. Kim, MD, Medallion Group Chair in Urology, co-medical director of the Urologic Oncology Center, associate director, Surgical Research in the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, discusses cytoreductive nephrectomy in patients with metastatic renal cell carcinoma.

The FDA has approved a supplemental biologics license application adding a 4-week dosing schedule for nivolumab across several of the PD-1 inhibitor’s indications.

Thai H. Ho, MD, PhD, discusses treatment advances in first-line RCC and how biomarker development and optimal sequencing are critical next steps to building on recent breakthroughs.

Ani Balmanoukian, MD, director of Thoracic Oncology, associate director of the Phase I Immune-Oncology Program, The Angeles Clinic and Research Institute, discusses immunotherapy advancements in genitourinary cancers.